Dawn of a new era come Monday 8th of January, page-27

It’s directed at the collective negative. As I indicated it contributes to an overwhelming negative sentiment at times that’s projected to, for instance, the over 3400 views this thread has had alone. It’s not helpful. It we are infact in the middle of negotiations at the moment, wouldn’t it be better to be negotiating from a higher sp? Of course it would so shareholders banging on about failed timelines etc is stupid. Particularly as timelines for clinical trials generally in biotec are missed 80% of the time. Recruitment issues and retention of that recruit to completion for instance. Starpharma are not special or alone with regard to those factors. But it’s projected by some frequent posters here that factors like these are somehow unique to us. They are not.